SeeTreat Medical
SeeTreat Medical is a Sydney-based medical device software company founded in 2023 that develops ART.1, an AI-driven offline adaptive radiotherapy platform providing automated replan decision support for radiation oncology departments worldwide.
- Company typePrivate
- Founded2023
- HeadquartersSydney, Australia
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What SeeTreat Medical does
SeeTreat Medical is a privately held software-as-a-medical-device company founded in 2023 in Sydney, Australia, by Dr Trang Nguyen and Prof Paul Keall. The company develops ART.1, an offline adaptive radiotherapy software platform that processes daily cone beam CT (CBCT) imaging to generate synthetic CTs, perform automatic image registration and contour propagation, calculate delivered dose against planned values using superposition/collapsed cone convolution algorithms, and surface per-patient replan decisions via a traffic-light dashboard. The product targets radiation oncology departments and cancer treatment centres, addressing the workflow burden of evaluating when a patient's radiotherapy plan should be adapted — a decision currently made manually in hours or days, which SeeTreat compresses to 95+ seconds per patient. Both cloud and on-premise deployment options are available, with universal compatibility with Varian and Elekta CT linear accelerators and no requirement for hardware upgrades.
SeeTreat monetises ART.1 through a software subscription or licence model sold via direct enterprise sales to radiation oncology networks. A flagship May 2026 partnership with GenesisCare covers 40+ Australian centres, with implementation scheduled from July 2026 following a 64-patient multidisciplinary study. The company operates across the United Kingdom, the European Union, Australia, and the United States, holding UKCA, CE Mark under EU MDR, Australian TGA ARTG, and FDA 510(k) clearances (May 2026), alongside ISO 13485 and MDSAP certifications. The go-to-market motion is enterprise field sales to large radiation oncology networks, with a consultative demo-led engagement model and content-driven thought leadership around adaptive radiotherapy. The leadership team combines deep radiation physics and medical device regulatory expertise, including former Stanford and TGA personnel.
SeeTreat Medical firmographics
Firmographics- Name
- SeeTreat Medical
- Legal name
- SeeTreat Pty Ltd
- Website
- https://seetreatmedical.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SeeTreat Medical is a Sydney-based medical device software company founded in 2023 that develops ART.1, an AI-driven offline adaptive radiotherapy platform providing automated replan decision support for radiation oncology departments worldwide.
- Ownership category
- akta.pro rank
SeeTreat Medical industry classification
Industry- Product category
- Adaptive Radiotherapy Software
- NAICS
- Diagnostic Imaging Centers (621512)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Radiation Oncology (HLAKAFAC)
- akta.pro secondary industries
- Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH), Radiation Dose Management & Analytics (HLACALAH), Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)
Keywords
Where SeeTreat Medical is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
SeeTreat Medical business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure, Supply Chain
Revenue model
- ART.1 Software License/Subscription: Software as a Medical Device (SaMD) sold to radiation oncology centres and cancer treatment providers. Revenue likely derived from subscription or license fees for clinical use of ART.1 software. Both cloud-based and on-premise deployment options available.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
SeeTreat Medical product offering
Product offeringCore offering
ART.1 is an offline adaptive radiotherapy software (Software as a Medical Device) that automatically evaluates radiation dose against each patient's changing anatomy at every treatment fraction. It ingests daily cone beam CT (CBCT) images, generates synthetic CTs, performs superposition dose calculation, runs automatic image registration and contour propagation, and surfaces replan decisions via a traffic-light dashboard for radiation oncology teams. The platform is sold on a subscription/license basis to hospitals, radiation oncology centres and cancer treatment networks in the UK, EU, Australia and the US.
Product overview
SeeTreat Medical offers a single unified product — ART.1 — an offline adaptive radiotherapy software platform. ART.1 provides automated adaptive decision support for radiation oncology teams, processing daily CBCT imaging to evaluate dose and anatomical changes for every patient at every treatment fraction. The software includes purpose-built image registration and dose calculation algorithms developed specifically for adaptive radiotherapy workflows. A regional variant, ART.1-US, is FDA cleared for the US market, while the core ART.1 holds UKCA mark, CE mark under EU MDR, and Australian ARTG registration for use in the UK, EU, and Australia. The product requires no hardware upgrades and integrates with existing Varian and Elekta linear accelerator systems.
Differentiator
Problem solved
Functional benefit
Products and services
- ART.1 ART.1 is an offline adaptive radiotherapy software (Software as a Medical Device) that ingests daily CBCT imaging, generates synthetic CTs, performs superposition dose calculation, runs automatic image registration and contour propagation, and provides objective, traffic-light decision support for when replanning may be warranted. It is intended for radiation oncology teams at hospitals and cancer treatment centres, with UKCA, CE Mark under EU MDR and Australian TGA ARTG (ARTG: 521207) clearances. Available via cloud or on-premise deployment; integrates with Varian and Elekta linear accelerators.
- ART.1-US ART.1-US is the FDA 510(k) cleared regional variant of ART.1 for clinical use in United States clinics equipped with Varian or Elekta CT linear accelerators. It enables clinical teams to evaluate radiotherapy dose to patients' changing anatomy in 95+ seconds and download supporting clinical documentation.
Quantifiable outcome
- Replan decision support in 95+ seconds per patient vs hours for manual review
- +3 more outcomes
Companies that use SeeTreat Medical
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles1 record
SeeTreat Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature6 records
SeeTreat Medical partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GenesisCareflagshipGenesisCare, Australia's leading cancer care provider, is collaborating with SeeTreat to deploy ART.1 software across more than 40 radiation oncology centres in Australia. Implementation is scheduled to begin July 2026. This follows a multidisciplinary study of the software on 64 head and neck, breast, and prostate cancer patients that demonstrated significant potential benefits in standardising and scaling adaptive treatment workflows. GenesisCare is the world's largest Radiation Therapy Network, treating over 35,000 people annually across more than 50 locations in Australia.
Scale indicators7 records
Recent moves5 records
Expansion highlights4 records
SeeTreat Medical competitors and assessment
Company assessmentDirect peers
- RaySearch Laboratories: Swedish developer of RayStation and RayCare, the leading third-party treatment planning and oncology information systems used by radiation oncology centres worldwide. Directly competes with ART.1 in radiation therapy planning and decision support software, with comparable target customer base and SaMD-style positioning.
- Brainlab: Medical software company offering Elements treatment planning, ExacTrac image guidance and oncology workflow tools to radiation oncology departments. Overlaps with ART.1 in radiation therapy planning, image registration and adaptive decision support for hospitals and cancer centres.
- MIM Software: Medical imaging analysis software company with products for radiation oncology (MIM Maestro) including auto-contouring, deformable registration and dose analytics. Closely comparable to ART.1 in the image-processing, contour propagation and dose-evaluation workflows used by radiation oncology centres.
- Mirada Medical: Oxford-based developer of radiation oncology software (XD, Workflow Box) for image registration, contouring and dose review. Directly comparable to ART.1 in providing software decision support for adaptive radiotherapy workflows to cancer treatment centres.
Broad incumbents
- Varian (a Siemens Healthineers company): Incumbent LINAC vendor (Eclipse, Ethos, ARIA) controlling a large share of the global radiation oncology installed base. Ethos is an adaptive radiotherapy solution that competes directly with SeeTreat's ART.1, while Varian's hardware dominance creates both an integration channel and a bundling threat for SeeTreat.
- Elekta: Incumbent LINAC vendor (Versa HD, Unity, MOSAIQ) with a sizeable installed base. Elekta's MOSAIQ oncology information system and Unity MR-LINAC adaptive workflows compete in the same radiation oncology software/adaptive therapy category as ART.1, and its hardware is a supported integration target for SeeTreat.
- Accuray: Developer of CyberKnife and TomoTherapy radiation therapy systems with associated Precision treatment planning software. Competes with SeeTreat in adaptive radiation oncology workflows, though Accuray operates more as a hardware-plus-software incumbent than a SaMD specialist.
Emerging players
- MVision AI: Finnish AI company providing automated radiotherapy contouring and treatment planning tools to cancer centres. Competes with SeeTreat in AI-driven decision support for radiation oncology but focuses primarily on auto-segmentation rather than full offline adaptive workflow automation.
- Therapanacea: Paris-based AI company building ART-Plan and other radiotherapy AI tools for treatment planning and adaptive workflows. Comparable to SeeTreat as a focused, AI-native adaptive radiotherapy software company targeting cancer centres, though earlier in commercial scale.
- Limbus AI: AI auto-contouring company whose products are widely used in radiation oncology for OAR and target segmentation. Overlaps with SeeTreat on the contour propagation and image analysis layer of the ART workflow but does not currently offer end-to-end adaptive decision support.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
SeeTreat Medical social profiles
Digital presenceSeeTreat Medical compliance and trust
Trust signalCompliance8 records
SeeTreat Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
SeeTreat Medical leadership team
Management profileNumber of profiles
Profiles9 records
SeeTreat Medical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SeeTreat Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SeeTreat Medical
What does SeeTreat Medical do?
ART.1 is an offline adaptive radiotherapy software (Software as a Medical Device) that automatically evaluates radiation dose against each patient's changing anatomy at every treatment fraction. It ingests daily cone beam CT (CBCT) images, generates synthetic CTs, performs superposition dose calculation, runs automatic image registration and contour propagation, and surfaces replan decisions via a traffic-light dashboard for radiation oncology teams. The platform is sold on a subscription/license basis to hospitals, radiation oncology centres and cancer treatment networks in the UK, EU, Australia and the US.
Is SeeTreat Medical a public or private company?
SeeTreat Medical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was SeeTreat Medical founded?
SeeTreat Medical was founded in 2023. It employs 11 to 50 people.
Where is SeeTreat Medical based?
SeeTreat Medical is headquartered in Sydney, Australia, in the Oceania region.
How does SeeTreat Medical make money?
One revenue line is on record: ART.1 Software License/Subscription.
Who are SeeTreat Medical's main competitors?
Direct peers on record are RaySearch Laboratories, Brainlab, MIM Software and Mirada Medical. Broad incumbents are Varian (a Siemens Healthineers company), Elekta and Accuray. Emerging players are MVision AI, Therapanacea and Limbus AI.
Does SeeTreat Medical have an API?
No public API is recorded for SeeTreat Medical.
What industry is SeeTreat Medical in?
SeeTreat Medical's product category is Adaptive Radiotherapy Software. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology, with a secondary code of HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim). Its NAICS code is 621512 and its SIC code is 3841.